69 related articles for article (PubMed ID: 24245692)
1. Suppression of NF-κB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer.
Wang LH; Yang JY; Yang SN; Li Y; Ping GF; Hou Y; Cui W; Wang ZZ; Xiao W; Wu CF
Curr Cancer Drug Targets; 2014; 14(1):91-103. PubMed ID: 24245692
[TBL] [Abstract][Full Text] [Related]
2. Metformin alleviates adriamycin resistance of osteosarcoma by declining YY1 to inhibit MDR1 transcriptional activity.
Wu B; Li P; Qiu E; Chen J
BMC Pharmacol Toxicol; 2023 Oct; 24(1):50. PubMed ID: 37828612
[TBL] [Abstract][Full Text] [Related]
3. NOD2 silencing promotes cell apoptosis and inhibits drug resistance in chronic lymphocytic leukemia by inhibiting the NF-κB signaling pathway.
Zheng C; Zhu Z; Weng S; Zhang Q; Fu Y; Cai X; Liu Z; Shi Y
J Biochem Mol Toxicol; 2023 Dec; 37(12):e23510. PubMed ID: 37700718
[TBL] [Abstract][Full Text] [Related]
4. Alangium longiflorum Merr. Leaf Extract Induces Apoptosis in A549 Lung Cancer Cells with Minimal NFκB Transcriptional Activation.
Marquez CMD; Garcia JG; Antonio JG; Jacinto SD; Velarde MC
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2453-2461. PubMed ID: 32856878
[TBL] [Abstract][Full Text] [Related]
5. Gambogic acid exhibits promising anticancer activity by inhibiting the pentose phosphate pathway in lung cancer mouse model.
Zhang Q; Zhang Y; Wang C; Tang H; Ma A; Gao P; Shi Q; Wang G; Shen S; Zhang J; Xia F; Zhu Y; Wang J
Phytomedicine; 2024 Jul; 129():155657. PubMed ID: 38692076
[TBL] [Abstract][Full Text] [Related]
6. IL-33/NF-κB/ST2L/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer.
Yang YE; Hu MH; Zeng YC; Tseng YL; Chen YY; Su WC; Chang CP; Wang YC
Cell Death Dis; 2024 May; 15(5):356. PubMed ID: 38778059
[TBL] [Abstract][Full Text] [Related]
7. Phytohemagglutinin from Phaseolus vulgaris enhances the lung cancer cell chemotherapy sensitivity by changing cell membrane permeability.
Wang P; Min S; Chen C; Hu J; Wei D; Wang X
J Nat Med; 2024 Mar; 78(2):355-369. PubMed ID: 38265611
[TBL] [Abstract][Full Text] [Related]
8. Subcellular localization and activity of gambogic acid.
Guizzunti G; Batova A; Chantarasriwong O; Dakanali M; Theodorakis EA
Chembiochem; 2012 May; 13(8):1191-8. PubMed ID: 22532297
[TBL] [Abstract][Full Text] [Related]
9. Natural gambogic acid-tuned self-assembly of nanodrugs towards synergistic chemophototherapy against breast cancer.
Lin B; Peng X; Cheng J; Wang J
J Mater Chem B; 2024 May; ():. PubMed ID: 38804636
[TBL] [Abstract][Full Text] [Related]
10. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
Wang S; Wang L; Chen M; Wang Y
Chem Biol Interact; 2015 Jun; 235():76-84. PubMed ID: 25824409
[TBL] [Abstract][Full Text] [Related]
11. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
Wang LH; Li Y; Yang SN; Wang FY; Hou Y; Cui W; Chen K; Cao Q; Wang S; Zhang TY; Wang ZZ; Xiao W; Yang JY; Wu CF
Br J Cancer; 2014 Jan; 110(2):341-52. PubMed ID: 24300974
[TBL] [Abstract][Full Text] [Related]
12. Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer.
Sun Y; Bao X; Ren Y; Jia L; Zou S; Han J; Zhao M; Han M; Li H; Hua Q; Fang Y; Yang J; Wu C; Chen G; Wang L
Cell Death Dis; 2019 May; 10(6):400. PubMed ID: 31127087
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors.
Han M; Jia L; Lv W; Wang L; Cui W
Front Oncol; 2019; 9():194. PubMed ID: 30984620
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of N-hydroxypropenamides based on adamantane to overcome resistance in NSCLC.
Bao X; Sun Y; Bao C; Zhang J; Zou S; Yang J; Wu C; Wang L; Chen G
Bioorg Chem; 2019 May; 86():696-704. PubMed ID: 30831531
[TBL] [Abstract][Full Text] [Related]
15. PAC-1 and its derivative WF-210 Inhibit Angiogenesis by inhibiting VEGF/VEGFR pathway.
Wang F; Wang L; Li Y; Wang N; Wang Y; Cao Q; Gong P; Yang J; Wu C
Eur J Pharmacol; 2018 Feb; 821():29-38. PubMed ID: 29269017
[TBL] [Abstract][Full Text] [Related]
16. Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors.
Wang NN; Wang LH; Li Y; Fu SY; Xue X; Jia LN; Yuan XZ; Wang YT; Tang X; Yang JY; Wu CF
Exp Cell Res; 2018 Jan; 362(1):72-82. PubMed ID: 29155365
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
Li Y; Wang LH; Zhang HT; Wang YT; Liu S; Zhou WL; Yuan XZ; Li TY; Wu CF; Yang JY
J Cell Mol Med; 2018 Jan; 22(1):439-451. PubMed ID: 29148232
[TBL] [Abstract][Full Text] [Related]
18. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Li M; Yang J; Zhou W; Ren Y; Wang X; Chen H; Zhang J; Chen J; Sun Y; Cui L; Liu X; Wang L; Wu C
Br J Cancer; 2017 Sep; 117(7):974-983. PubMed ID: 28850563
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of SL4 against breast cancer cells: induction of G
Wang LH; Jiang XR; Chen GL; Guo W; Zhang JY; Cui LJ; Li HH; Li M; Liu X; Yang JY; Wu CF
Sci Rep; 2016 Nov; 6():36486. PubMed ID: 27819344
[TBL] [Abstract][Full Text] [Related]
20. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
